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We compared conﬁ  rmed pandemic (H1N1) 2009 in-
ﬂ   uenza and seasonal inﬂ   uenza diagnosed in Western 
Australia during the 2009 inﬂ  uenza season. From 3,178 
eligible reports, 984 pandemic and 356 seasonal inﬂ  uen-
za patients were selected; 871 (88.5%) and 288 (80.9%) 
were interviewed, respectively. Patients in both groups re-
ported a median of 6 of 11 symptoms; the difference be-
tween groups in the proportion reporting any given symp-
tom was <10%. Fewer than half the patients in both groups 
had >1 underlying condition, and only diabetes was as-
sociated with pandemic (H1N1) 2009 inﬂ  uenza (odds ratio 
[OR] 1.9, 95% conﬁ  dence interval [CI] 1.1–3.5). A total of 
129 (14.8%) persons with pandemic (H1N1) 2009 and 36 
(12.5%) persons with seasonal inﬂ   uenza were hospital-
ized (p = 0.22). After controlling for age, we found that pa-
tient hospitalization was associated with pandemic (H1N1) 
2009 inﬂ   uenza (OR 1.5; 95% CI 1.1–2.1). Contempora-
neous pandemic and seasonal inﬂ  uenza infections were 
substantially similar in terms of patients’ symptoms, risk 
factors, and proportion hospitalized.
P
andemic (H1N1) 2009 inﬂ  uenza A emerged in Mexico 
in March 2009 and was ﬁ  rst reported in the United States 
the following month, toward the close of the 2008–09 in-
ﬂ  uenza season in the Northern Hemisphere (1,2). The virus 
rapidly spread worldwide, with the ﬁ  rst pandemic (H1N1) 
2009 infection reported in Australia on May 9, 2009, just 
before the start of the traditional winter inﬂ  uenza season in 
the Southern Hemisphere (3).
There are little data directly comparing conﬁ  rmed 
pandemic (H1N1) 2009 with contemporaneous seasonal 
inﬂ  uenza over the same inﬂ  uenza season (4–6). Many of 
the reports on the epidemiology of inﬂ  uenza in 2009 to 
date have focused exclusively on pandemic (H1N1) 2009 
or have used limited laboratory-based surveillance data on 
isolation rates for seasonal and pandemic (H1N1) 2009 in-
ﬂ  uenza viruses (7–13). Other reports have compared pan-
demic (H1N1) 2009 and seasonal inﬂ  uenza infections that 
occurred outside the usual inﬂ  uenza season (14). Still other 
investigators have compared various indicators of inﬂ  u-
enza severity during the current pandemic with historical 
data from previous annual inﬂ  uenza epidemics (15,16). In-
terpretation of such comparisons is challenging because of 
variation in inﬂ  uenza activity from season to season. Fur-
thermore, heightened awareness surrounding the current 
pandemic may have affected patient care-seeking behavior 
or physician diagnostic practices, thus potentially creating 
bias in year-to-year comparisons. Examining conﬁ  rmed 
pandemic (H1N1) 2009 and seasonal inﬂ  uenza infections 
occurring in the same population during the 2009 inﬂ  uenza 
season enables a more straightforward comparison.
We interviewed persons with laboratory-conﬁ  rmed 
pandemic (H1N1) 2009 or seasonal inﬂ  uenza  infection 
over a 10-week period encompassing the peak of the winter 
inﬂ  uenza season. This effort enabled us to directly com-
pare the clinical illness and predisposing medical risk fac-
tors associated with pandemic (H1N1) 2009 and seasonal 
inﬂ   uenza infections diagnosed contemporaneously from 
the general population of Western Australia, which has a 
population of 2.2 million persons.
Methods
All clinical laboratories report positive inﬂ  uenza test 
results to the Communicable Disease Control Directorate 
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(CDCD), Department of Health, Western Australia. For 
diagnosis, respiratory samples, usually combined nose and 
throat swab specimens, were tested by PCR. More than 90% 
of the specimens were tested at PathWest Laboratory Medi-
cine Western Australia, Queen Elizabeth II Medical Centre, 
by using an assay that identiﬁ  ed and distinguished between 
pandemic (H1N1) 2009 and seasonal inﬂ  uenza A/H1, A/H3, 
and B (17); positive results for pandemic (H1N1) 2009 inﬂ  u-
enza virus reported from other clinical laboratories were con-
sidered as single infections with pandemic (H1N1) 2009.
Reports of all PCR-conﬁ  rmed  inﬂ  uenza  infections 
were reviewed. Patients were excluded if the results could 
not differentiate between pandemic and seasonal viruses 
or if the patient was identiﬁ  ed as infected with pandemic 
(H1N1) 2009 and seasonal inﬂ  uenza. Pandemic inﬂ  uenza 
was deﬁ   ned as PCR-conﬁ   rmed pandemic (H1N1) 2009 
inﬂ  uenza infection, and seasonal inﬂ  uenza was deﬁ  ned as 
any PCR-conﬁ  rmed inﬂ  uenza infection for which infection 
with pandemic (H1N1) 2009 virus had been excluded.
The study began May 29, 2009 (1 week after the ill-
ness onset in the ﬁ  rst person with conﬁ  rmed pandemic 
[H1N1] 2009 inﬂ   uenza infection in Western Australia) 
and concluded August 7, 2009 (Figure 1) (18). From the 
study inception through July 13, 2009, attempts were made 
to interview every patient with conﬁ  rmed  inﬂ  uenza  ill-
ness reported to CDCD. On July 14, 2009, we instituted 
a sampling framework because of increasing numbers of 
reported infections. The sampling scheme entailed identi-
fying the last digit of a sequentially-assigned identiﬁ  cation 
number from the ﬁ  rst patient reported each day with sea-
sonal or pandemic (H1N1) 2009 inﬂ  uenza, then selecting 
all patients reported that day with the same last digit. If 
<20 patients were identiﬁ  ed for interview, we added 1 to 
the digit (n + 1) and selected additional patients by using 
the same procedure. This process was repeated until up to 
20 persons with seasonal inﬂ  uenza and 20 with pandemic 
inﬂ  uenza were chosen each day. If <20 inﬂ  uenza infections 
were reported on a given day for either seasonal or pan-
demic (H1N1) 2009 inﬂ  uenza, we attempted to interview 
all patients reported on that day.
Study participants were interviewed by a trained nurse 
who used a standard questionnaire. If a patient was unable 
to answer questions or was <18 years of age, the nurse in-
terviewed a parent or other family member familiar with 
the patient’s situation. We made 6 attempts to contact the 
patient or a proxy, after which the patient was considered 
not contactable. Diagnostic specimens of participating 
patients were collected a median of 2 d after illness onset 
(interquartile range [IQR] 1–3 d), and patients were inter-
viewed a median of 6 d after onset (IQR 5–8 d).
The patient’s self-reported symptoms, treatment with 
antiviral medications, presence of underlying medical con-
ditions, and disease disposition were recorded. Information 
on hospitalization was obtained at the time of the interview 
and by retrospectively querying a hospital discharge data-
base that covers all public hospitals in the state and 1 major 
private metropolitan facility. A cross-check with the hospi-
tal discharge database was performed for every inﬂ  uenza 
notiﬁ  cation received at CDCD.
For our analysis, we ﬁ  rst characterized all patients with 
pandemic (H1N1) 2009 or seasonal inﬂ  uenza infection re-
ported to CDCD during the study period (the target popu-
lation) in terms of age, sex, and hospitalization status by 
using univariate Mantel-Haenszel χ2 tests for proportions 
and t tests for population means. We then compared pa-
tients who were interviewed (the study population) with the 
remaining patients not interviewed in the target population 
in terms of age, sex, and hospitalization status; if a signiﬁ  -
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Figure 1. Number of notiﬁ  cations for pandemic and seasonal inﬂ  uenza, by date of onset and type, Western Australia, May 22–September 
11, 2009. Inﬂ  uenza subtypes reported during the study period (n = 3,178): pandemic (H1N1) 2009, 2,794 (87.9%); inﬂ  uenza A (H3N2), 253 
(8.0%); seasonal inﬂ  uenza A (H1N1), 89 (2.8%); inﬂ  uenza B, 36 (1.1%); and seasonal inﬂ  uenza A (not subtyped), 6 (0.2%).RESEARCH
cant difference was identiﬁ  ed, we weighted the interview 
responses from the study participants to reﬂ  ect the target 
population (19). Finally, by using the data obtained during 
interviews, we performed univariate analyses to compare 
patients with pandemic inﬂ  uenza with those with seasonal 
inﬂ  uenza with respect to reported symptoms, underlying 
medical conditions, and treatment. Because the age struc-
ture of the population with pandemic inﬂ  uenza differed 
from that with seasonal inﬂ  uenza, we also computed odds 
ratios (ORs) for individual symptoms or underlying medi-
cal conditions by using logistic regression to control for 
age. In each of the regression analyses, the dependent vari-
able was deﬁ  ned as inﬂ  uenza type (pandemic/seasonal), 
and the independent variables were limited to age in years 
and 1 dichotomous variable representing the presence or 
absence of a single patient characteristic (e.g., a symptom 
or underlying medical condition).
To assess whether antiviral medications might have 
inﬂ  uenced the symptoms reported, we performed a sub-
analysis restricted to patients who were treated with antivi-
ral agents within the ﬁ  rst 2 days of illness onset (early use 
of antiviral drugs) and compared those patients with pa-
tients who were never treated, controlling for age, inﬂ  uenza 
type, and the presence of underlying medical conditions.
Inﬂ  uenza-like illness was deﬁ  ned as documented fe-
ver >38°C or a history of fever when the temperature was 
not known, and cough or sore throat, or both. Risk differ-
ence was deﬁ  ned as the absolute difference in the propor-
tion of pandemic and seasonal inﬂ  uenza patients reporting 
a given parameter. A p value <0.05 was considered sig-
niﬁ  cant. Statistical analyses were performed by using Epi 
Info 2000 (Centers for Disease Control and Prevention, 
Atlanta, GA, USA).
Results
Characteristics of the Target Population
A total of 3,313 notiﬁ  cations of laboratory-conﬁ  rmed 
inﬂ  uenza were received at CDCD during the study period. 
Of these notiﬁ  cations, 117 (3.5%) were excluded because 
information on the viral strain and/or subtype was incom-
plete, and 18 (0.5%) were excluded because pandemic and 
seasonal inﬂ  uenza viruses were detected (Figure 2). Of 
the remaining 3,178 inﬂ  uenza infections reported, 2,794 
(87.9%) were pandemic (H1N1) 2009 inﬂ  uenza and 384 
(12.1%) were seasonal inﬂ  uenza. The proportion of each 
inﬂ  uenza subtype identiﬁ  ed is shown in the inset in Figure 
1. The mean age of patients with pandemic inﬂ  uenza was 
signiﬁ  cantly lower than that for patients with seasonal in-
ﬂ  uenza, 27 and 35 years, respectively (p<0.005).
Most of the pandemic and seasonal inﬂ  uenza patients 
were female, but the proportion of female patients among 
the seasonal inﬂ  uenza patients was signiﬁ  cantly greater 
than that among patients with pandemic inﬂ  uenza, 57.3% 
(220/384) and 51.2% (1,431/2,794), respectively (p = 0.03 
by χ2 test). However, the association between female sex 
and seasonal inﬂ  uenza was not signiﬁ  cant when we con-
trolled for age (p = 0.09).
A total of 415 (14.9%) of the 2,794 patients with pan-
demic inﬂ  uenza and 48 (12.5%) of the 384 patients with sea-
sonal inﬂ  uenza were hospitalized. The difference between 
proportion of patients hospitalized with pandemic and sea-
sonal inﬂ  uenza was not signiﬁ  cant on univariate analysis 
(p = 0.22, by χ2 test). However, when we controlled for 
age, the odds of hospitalization were signiﬁ  cantly greater 
for persons with pandemic inﬂ  uenza (OR 1.53, 95% conﬁ  -
dence interval [CI] 1.10–2.13; p = 0.011).
Selection and Representativeness 
of Study Participants
A total of 984 patients with pandemic (H1N1) 2009 
inﬂ  uenza and 356 patients with seasonal inﬂ  uenza were 
selected for interview, and 871 (88.5%) and 288 (80.9%) 
of selected patients completed the interview, respectively 
(Figure 2). Of the 181 patients selected but not interviewed, 
168 were not able to be contacted because they did not have 
a working telephone number or did not answer after 6 at-
tempts, and 13 declined to participate.
Patients who completed interviews were very simi-
lar to the remaining notiﬁ  ed inﬂ  uenza patients who were 
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Figure 2. Recruitment of pandemic and seasonal inﬂ  uenza study 
participants, Western Australia, 2009.Inﬂ  uenza, Western Australia, 2009
not interviewed with respect to age and sex. The median 
age was 25 years (IQR 13–42 years) for study participants 
and 25 years (IQR 14–39 years) for the remaining notiﬁ  ed 
inﬂ  uenza patients who were not interviewed. Women and 
girls accounted for 51.0% (591/1,159) of the study partic-
ipants and 52.5% (1,060/2,019) of the remaining patients 
with notiﬁ  ed inﬂ  uenza cases who were not interviewed (p 
= 0.41, by χ2 test).
Hospitalized persons were underrepresented among 
the study participants compared with the remaining inﬂ  u-
enza case-patients who were not interviewed, i.e., 11.9% 
(138/1,159) of the interviewed patients had been hospital-
ized compared with 16.1% (325/2,019) of the patients not 
interviewed (p<0.05). The interview data were therefore 
weighted to reﬂ  ect the hospitalization rate in the target 
population for both pandemic and seasonal inﬂ  uenza.
Comparison of Pandemic and Seasonal Inﬂ  uenza 
in the Study Population
The age distribution for study participants, by inﬂ  u-
enza type, is shown Figure 3. As in the target population, 
the mean age of study participants with pandemic (H1N1) 
2009 inﬂ  uenza was signiﬁ  cantly younger than the mean 
age of study participants with seasonal inﬂ  uenza, 26 and 
36 years, respectively (p<0.005). Only 6% (49/871) of the 
study participants with pandemic inﬂ  uenza were >55 years 
of age compared with 23% (65/288) of those with seasonal 
inﬂ  uenza (p<0.005).
The distribution of the total number of symptoms re-
ported by each patient with pandemic or seasonal inﬂ  uenza 
is shown in Figure 4. Patients with pandemic inﬂ  uenza and 
seasonal inﬂ  uenza reported a median of 6 symptoms (IQR 
5–8 symptoms and 4–8 symptoms, respectively). When we 
controlled for age, no signiﬁ  cant association was found be-
tween inﬂ  uenza type and the total number of symptoms that 
patients reported (p = 0.19).
The number and proportion of patients reporting spe-
ciﬁ  c symptoms are presented in the Table. The difference 
in the proportion reporting a given symptom between pa-
tients with pandemic and seasonal inﬂ  uenza was <10% for 
all symptoms. Univariate analyses showed that fever and 
diarrhea were signiﬁ  cantly more common for patients with 
pandemic inﬂ  uenza. Controlling for age added cough and 
myalgia/arthralgia to the symptoms signiﬁ  cantly associated 
with pandemic (H1N1) 2009 inﬂ  uenza compared to those 
with seasonal inﬂ  uenza. Rhinorrhea was signiﬁ  cantly as-
sociated with seasonal inﬂ  uenza on univariate analysis, and 
this association persisted when controlling for age.
The distribution of the total number of underlying 
medical conditions reported by individual patients with 
pandemic (H1N1) 2009 or seasonal inﬂ  uenza is shown in 
Figure 5. Just over half of the patients with seasonal or pan-
demic inﬂ  uenza had no underlying medical condition(s).
The proportion of patients who reported a speciﬁ  c un-
derlying medical condition is presented in the Table. The 
absolute difference in the proportion of patients that re-
ported a given medical condition between those with pan-
demic (H1N1) 2009 and seasonal inﬂ  uenza was greatest for 
pregnant patients but still <5% for all underlying conditions 
queried. None of the 11 underlying medical conditions we 
queried were signiﬁ  cantly associated with pandemic or sea-
sonal inﬂ  uenza in univariate analysis. When controlling for 
age, we found that only the odds of reporting a history of 
diabetes were signiﬁ  cantly greater among patients with pan-
demic inﬂ  uenza (OR 1.93, 95% CI 1.07–3.51; p = 0.03).
Having >1 underlying medical condition was not sig-
niﬁ  cantly associated with pandemic inﬂ  uenza in the uni-
variate analyses. However, after we controlled for age, we 
observed that the odds of reporting >1 underlying medical 
conditions were signiﬁ  cantly greater among patients with 
pandemic inﬂ  uenza (Table).
By design, the analysis that used weighted data shown 
in the Table mirrors the hospitalization rates observed for 
pandemic and seasonal inﬂ  uenza in the target population 
(14.9% vs. 12.5%, p = 0.22). The distribution of the length 
of stay for hospitalized study participants is shown in Fig-
ure 6. The mean duration of hospitalization was 5.1 d (me-
dian 3 d, IQR 2–6 d) for patients with pandemic inﬂ  uenza 
and 3.4 d (median 2 d, IQR 1–4 d) for those with seasonal 
inﬂ  uenza (p = 0.13). Although the ﬁ  ndings were not sig-
niﬁ  cant, a trend toward longer hospital stays did appear for 
those with pandemic (H1N1) 2009 versus seasonal illness, 
based on the proportion of patients hospitalized an addi-
tional >7 d (21% vs. 8%, p = 0.07).
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Figure 3. Age distribution 
for study participants, by 
inﬂ   uenza type, Western 
Australia, 2009.RESEARCH
Of the 10 patients hospitalized for >14 d, all had >1 
underlying medical condition, and 6 had >2 conditions. 
Two patients in the study population died; both had pan-
demic (H1N1) 2009.
The proportion of patients reporting treatment with 
antiviral medication was signiﬁ  cantly greater among those 
with pandemic inﬂ  uenza (Table). Information on the type 
of antiviral drug received was recorded for 427 (94.9%) of 
450 patients treated with antiviral drugs; 426 reported tak-
ing oseltamivir and 1 reported taking zanamivir. The mean 
lag time between illness onset and starting antiviral treat-
ment was 2.7 d (median 2 d, IQR 1–3 d) for patients with 
pandemic inﬂ  uenza and 2.3 d (median 2 d, IQR 1–3 d) for 
patients with seasonal inﬂ  uenza (p = 0.39).
Comparing patients given antiviral medications with 
those who were not, we found a signiﬁ  cant inverse relation-
ship (i.e., a protective effect) between early antiviral drug 
use and reported rhinorrhea for patients with pandemic in-
ﬂ  uenza (OR 0.5, 95% CI 0.4–0.8; p = 0.005). We also ob-
served a positive association between early antiviral drug 
use and nausea and vomiting; this association was robust 
and persisted when the analysis was simultaneously con-
trolled for age, inﬂ  uenza type, underlying conditions, as 
well as other symptoms commonly associated with inﬂ  u-
enza and/or gastrointestinal illness (i.e., fever, cough, sore 
throat, diarrhea) (OR 1.6, 95% CI 1.2–2.1; p = 0.02). No 
other symptoms were associated, positively or negatively, 
with antiviral drug use in the ﬁ  rst 2 days of illness onset.
Discussion
This comparison of >1,000 total conﬁ  rmed seasonal 
and pandemic (H1N1) 2009 inﬂ  uenza infections occurring 
contemporaneously over the peak of the traditional inﬂ  u-
enza season yielded several ﬁ  ndings. First, the spectrum of 
clinical illness due to pandemic inﬂ  uenza was similar to 
that caused by seasonal inﬂ  uenza. Although several symp-
toms were more common in patients with pandemic inﬂ  u-
enza, the differences were modest and of limited clinical 
importance. 
Our ﬁ  ndings generally parallel those from a recent com-
parative analysis in Singapore, with some differences. For 
example, in Singapore, the proportions of patients with sea-
sonal and pandemic inﬂ  uenza who reported diarrhea were 
0% and 4%, respectively; these ﬁ   gures are substantially 
lower than those found in our study (12% and 19%, respec-
tively), despite the fact that in both settings most nonpan-
demic inﬂ  uenza viruses identiﬁ  ed were inﬂ  uenza A (H3N2). 
These differences highlight the need to consider data from 
diverse geographic, cultural, and healthcare environments 
when characterizing the clinical manifestations of inﬂ  uenza.
Second, we observed that the hospitalization rates for 
pandemic (H1N1) 2009 and seasonal inﬂ  uenza infections 
were similar. Our ability to use a comprehensive statewide 
database to identify hospital admissions in the broader tar-
get population permitted a robust analysis that found the 
overall proportion of conﬁ   rmed pandemic and seasonal 
illnesses hospitalized was not signiﬁ  cantly different when 
aggregated data were used in univariate analyses (p>0.05). 
However, if the analysis was controlled for age, the odds of 
being hospitalized were signiﬁ  cantly greater for the popu-
lation with pandemic inﬂ  uenza. These seemingly dissonant 
results actually reﬂ  ect the fact that for many age groups 
there was a higher risk for hospitalization with pandemic 
(H1N1) 2009, but because patients with seasonal inﬂ  uenza 
were older relative to those with pandemic inﬂ  uenza and 
elderly patients are more likely to be admitted to hospital 
when ill with inﬂ  uenza, the cumulative hospitalization rate 
in the 2 patient groups was similar.
In addition, in this study, the mean duration of hos-
pitalization was not statistically different between patients 
with pandemic (H1N1) 2009 and seasonal inﬂ  uenza even 
though other indicators suggested pandemic patients were 
hospitalized for longer periods. An analysis of a larger 
sample of hospitalized patients is under way.
Third, the underlying medical conditions associated 
with pandemic (H1N1) 2009 and seasonal inﬂ  uenza ill-
nesses diagnosed in the community were nearly identical 
in terms of the type and number of conditions reported. 
Most patients in both groups reported no risk factors, and 
only when we controlled for age did we ﬁ  nd an associa-
tion between having >1 underlying medical condition and 
pandemic inﬂ  uenza. Notably, the largest risk difference we 
observed was for was pregnancy (4%). Univariate analyses 
showed that the association between pregnancy and pan-
demic inﬂ  uenza approached statistical signiﬁ  cance (p = 
0.08; analysis not shown). When we restricted our analysis 
to women 15–45 years of age, the risk difference nearly 
doubled, but signiﬁ  cance was still not attained, perhaps 
as a consequence of the smaller sample size. Seasonal 
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Figure 4. Number of symptoms reported by study participants with 
inﬂ  uenza, by inﬂ  uenza type, Western Australia, 2009.Inﬂ  uenza, Western Australia, 2009
inﬂ  uenza is a well-established cause of serious illness dur-
ing pregnancy, and several reports indicate that the risk for 
severe illness from pandemic (H1N1) 2009 may be even 
greater (20–23).
Obesity, newly recognized as a risk factor for severe 
inﬂ  uenza illness during the 2009 pandemic, was reported as 
often by patients with seasonal inﬂ  uenza as by those with 
pandemic inﬂ  uenza (11% vs. 9%; p>0.05). This ﬁ  nding 
suggests that obesity may be equally important as a risk 
factor for seasonal and pandemic (H1N1) 2009 (24).
Finally, because our study was not a randomized con-
trolled trial, inferences about the effect of antiviral medi-
cations should be viewed with caution. For example, our 
observation that antiviral drug use was negatively associ-
ated with reported rhinorrhea may be due to the effect of 
treatment or may have resulted from a relative disinclina-
tion of providers to prescribe antiviral drugs for patients 
with rhinorrhea, on the basis of an assumption that na-
sal symptoms make inﬂ  uenza infection less likely (25). 
However, the robust positive association we observed in 
our population between antiviral agent use and nausea/
vomiting suggests that there was a causal relationship, a 
conclusion consistent with that of a recent metaanalysis 
on oseltamivir use (26).
The limitations of our study include the following: re-
ported underlying medical conditions were not objectively 
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Table. Symptoms, underlying medical conditions, and medical care reported by study participants in a comparison of pandemic 
(H1N1) 2009 and seasonal influenza, Western Australia, 2009* 
Parameter
No.
respondents 
Pandemic
(H1N1) 2009, 
no. (%) 
Seasonal
influenza,
no. (%)  RD
Univariate F
2
p value OR† (95% CI) p value
Symptoms 
  Fever‡  1,159  762 (88)  225 (78)  10 0.001  1.64 (1.15–2.35)  0.01§ 
  Cough  1,159  743 (85)  236 (82)  3 NS 1.45 (1.01–2.34)  0.01§ 
  Myalgia/arthalgia  1,159  565 (65)  173 (60)  5 NS 1.40 (1.06–1.87)  0.02§ 
  Diarrhea  1,159  165 (19)  35 (12)  7 0.008  1.72 (1.15–2.57)  0.01§ 
  Rhinorrhea  1,159  494 (57)  189 (66)  9 0.007 0.60  (0.45–0.80)  0.01§ 
  Sore throat  1,159  488 (56)  169 (59)   3 NS 0.82 (0.62–1.09)  0.17
  Shortness of breath  1,159  289 (33)  99 (35)  2 NS 1.14 (0.85–1.53)  0.38
  Headache  1,159  537 (62)  176 (61)  1 NS 1.02 (0.77–1.35)  0.91
  Vomiting or nausea  1,159  284 (33)  80 (28)  5 NS 1.14 (0.84–1.54)  0.40
  Fatigue  1,159  639 (73)  205 (71)  2 NS 1.12 (0.83–1.51)  0.47
  Rigors  1,159  471 (54)  148 (52)  2 NS 1.13 (0.86–1.48)  0.40
  ILI criteria met¶  1,159  706 (81  209 (73)  8 0.002  1.50 (1.09–2.06)  0.01§ 
Underlying medical conditions
  Diabetes  1,032  49 (7)  18 (6)  1 NS 1.93 (1.07–3.51)  0.03§ 
  Heart disease  1,027  34 (5)  20 (7)  2 NS 1.16 (0.63–2.16)  0.63
  Respiratory disease  1,031  178 (24)  62 (22)  2 NS 1.33 (0.94–1.87)  0.10
  Renal disease  1,028  13 (2)  7 (2)  0 NS 1.17 (0.44–3.10)  0.76
  Neurologic disease  1,028  12 (2)  7 (2)  0 NS 0.91 (0.33–2.53)  0.86
  Hematologic disorder  1,028  19 (3)  5 (2)  1 NS 2.33 (0.82–6.66)  0.11
  Metabolic disease (not diabetes)  1,028  12 (2)  4 (1)  1 NS 1.25 (0.38–4.06)  0.71
  Immune impairment  1,028  26 (3)  16 (6)  3 NS 0.88 (0.45–1.71)  0.70
  Morbid obesity  1,031  64 (9)  32 (11)  2 NS 1.12 (0.70–1.80)  0.64
  Current smoker  1,032  98 (13)  35 (12)  1 NS 1.36 (0.89–2.08)  0.16
  Pregnancy (women only)  556 36 (9)  8 (5)  4 NS 1.85 (0.84–4.10)  0.13
  Any  1,051  366 (48)  135 (47)  1 NS 1.44 (1.07–1.94)  0.02§ 
Medical care 
  Hospitalization  1,159  129 (15)  36 (12)  3 NS 1.58 (1.04–2.39)  0.03§ 
  Antiviral treatment  1,103  388 (47)  71 (26)  21 0.001  3.12 (2.27–4.29)  0.01§ 
*Totals respondents may not sum to 1,159 for all parameters because questions regarding underlying medical conditions and antiviral treatment were 
added shortly after the study was initiated, and there are intermittent missing values to individual questions for some respondents. RD, risk difference 
(absolute difference in the proportion of pandemic and seasonal influenza patients reporting a given parameter); OR, odds ratio; CI, confidence interval; 
NS, not significant; ILI, influenza–like illness (patient had fever and cough or sore throat). 
†ORs were computed by using logistic regression to control for age. Each row depicts data from a separate regression equation, where the dependent 
variable was defined as influenza type and age (in years) and a single patient characteristic, as listed in the first column of the row (coded as a 
dichotomous variable indicating the presence or absence of the respective symptom or underlying medical condition) were included as the predictor 
variables. In all of the logistic analyses performed, age remained significantly associated with influenza type, i.e., younger patients had a higher odds of 
having pandemic influenza compared with seasonal influenza. 
‡Fever was defined as temperature >38qC or subjective fever if temperature was not measured. 
§Significant OR obtained using logistic regression. 
¶ Patient reported >1 of the underlying medical conditions listed. RESEARCH
veriﬁ  ed, data on the duration of symptoms were not col-
lected, and interviewers were not blinded to inﬂ  uenza type 
when administering the questionnaire. Also, because this 
was a public health evaluation of notiﬁ  ed inﬂ  uenza infec-
tions principally detected through routine healthcare prac-
tices in the community at large, we were unable to control 
for potential biases stemming from who was tested and 
who was not. However, because the healthcare provider 
could not be conﬁ  dent of whether the patient had pandemic 
(H1N1) 2009 or seasonal inﬂ  uenza at the time of testing, 
any bias in who was selected for testing should be approxi-
mately equal for pandemic (H1N1) 2009 and seasonal in-
ﬂ  uenza patient groups. Lastly, a limitation inherent in the 
case–control study design we used was that we are unable 
to assess the extent to which the underlying medical condi-
tions reported increased the risk for a diagnosis of inﬂ  uenza 
of either type, when compared with persons without under-
lying medical conditions.
In summary, our head-to-head comparison of conﬁ  rmed 
pandemic (H1N1) 2009 and contemporaneous seasonal in-
ﬂ  uenza infections found little to differentiate the 2 in terms 
of symptoms, underlying medical conditions, and the pro-
portion of patients hospitalized. These results add to the 
growing body of knowledge about pandemic (H1N1) 2009 
and are in general agreement with several studies that used 
different methods in other settings (27). These data are im-
portant because early in the pandemic some reports espoused 
different conclusions; 1 report estimated the lethality of pan-
demic (H1N1) 2009 to be ≈1 death per 10,000 infections, 
about 100× greater than that for regular seasonal inﬂ  uenza 
(28,29). Worldwide, unprecedented levels of resources have 
been expended to mitigate the impact of pandemic (H1N1) 
2009. In the United States alone, the federal government ap-
propriated $7.65 billion for this effort (30). This commitment 
to controlling pandemic (H1N1) 2009 is to be lauded, but we 
must not lose sight of the fact that seasonal inﬂ  uenza remains 
an important, albeit relatively uncelebrated, cause of illness 
and death each year. As the pandemic (H1N1) 2009 response 
draws to a close, it may be prudent to revisit the level of ef-
fort directed toward reducing the enormous effects, in terms 
of costs and health outcomes, associated with annually re-
curring inﬂ  uenza epidemics (31).
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